Windlas Biotech Gets GMP Certification for Its Injectable Facility

Windlas Biotech, an esteemed pharmaceutical enterprise headquartered in India, excels in the manufacturing and distribution of a diverse portfolio of generic pharmaceutical products, over-the-counter (OTC) medicines, and active pharmaceutical ingredients (APIs). 

Received GMP Certification

The prestigious certification, bestowed by the Food Safety & Drugs Administration Authority of Uttarakhand, follows a meticulous inspection conducted in December 2024. In a regulatory filing, the company affirmed that the certification acknowledges its adherence to Good Manufacturing Practices (GMP) in line with the World Health Organization’s (WHO) TRS Guidelines.

Windlas Biotech Management Stated

Hitesh Windlass, Managing Director of Windlas Biotech, remarked, “This certification heralds a transformative chapter in Windlas Biotech’s growth journey, enhancing our stature as a trusted leader in the pharmaceutical manufacturing domain. It underscores our steadfast commitment to quality, innovation, and compliance with the most rigorous regulatory standards. 

The GMP accreditation for our injectable facility not only validates our dedication to stringent manufacturing protocols but also fortifies our capability to address the burgeoning demand for premium injectable pharmaceutical products across domestic and global markets.”

Windlas Biotech CDMO

With this latest GMP-certified injectable facility, all 5 manufacturing plants operated by Windlas Biotech now conform to this gold standard. The company is strategically poised to broaden its product portfolio within the CDMO (Contract Development and Manufacturing Organisation) sector, enabling it to address a wider array of therapeutic areas. 

This pivotal advancement enhances access to essential medicines, improves patient outcomes, and positions Windlas Biotech as a pivotal player in the global pharmaceutical landscape.

Share Price Performance 

Windlas Biotech Ltd shares were traded at ₹920.70 per share on the NSE at 2:00 PM.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.